A signal seeking window trial of AZD8931 in patients with resectable non-small cell lung cancer
Read time: 1 mins
Last updated:30th Jul 2012
The primary objective of the study is to determine whether a 40mg twice daily dose of AZD8931 administered for 10-14 days (up to 18 days if surgery recheduled) results in suppression of cancer cell growth, by looking at changes in a marker called Ki67, which represents proliferation of tumour cells, before and after treatment with AZD8931.
|Study start date||2012-07-30|